All News
Rheumatoid Arthritis Offspring Show Normal School Performance
A prospective, longitudinal study of the cognitive development of children born to mothers with rheumatoid arthritis (RA) demonstrates normal development as measured by comparative school test scores.
Read Article
FDA Approves Anifrolumab in SLE
AstraZeneca announced today that anifrolumab (Saphnelo or anifrolumab-fnia) was approved by the the Food and Drug Administration (FDA) for that treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy.
Read Article
Shingles Risk with JAK Inhibitors and Other Biologics
Registry data suggests an increased risk of herpes zoster (HZ, shingles) in rheumatoid arthritis (RA) patients taking JAK inhibitors (JAKi) but also with other biologic DMARDs, compared to csDMARDs.
Read Article
No Cancer Risk with TNF Inhibitors in Rheumatoid Arthritis
The ARTIS Study Group has published their analysis of (non-skin) cancer risk in rheumatoid arthritis, claiming the overall safety of biologic DMARDs and targeted synthetic DMARDs (tsDMARDs).
Read Article
Combo Methotrexate and Leflunomide Safety in RA
Methotrexate and leflunomide (LEF) are the most widely prescribed DMARDs worldwide; yet biologic DMARDs are the newest and best selling agents for rheumatoid arthritis worldwide.
Read Article
Cardiovascular Prevention Lacking in Rheumatoid Arthritis
An increased cardiovascular disease (CVD) risk in rheumatoid arthritis is well known and feared but an RA cohort study suggests that preventive medication use in RA patients lags behind that seen in diabetes mellitus (DM).
Read Article
DMARD Effects on COVID-19 Outcomes
Sparks and colleagues have published data from the Global Rheumatology Alliance noting that among rheumatoid arthritis (RA) patients afflicted with COVID-19 infection, there was little influence of their baseline biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drug
Read Article
Tofacitinib Efficacy in Ankylosing Spondylitis
Deodhar and colleagues have published the results of a study showing that in adult patients with active ankylosing spondylitis (AS), oral tofacitinib was effective (versus placebo) and is safe.
Read Article
New-Onset IBD and IL-17 Inhibitors: What Is the Risk?
Patients with inflammatory/autoimmune diseases who initiated treatment with interleukin (IL)-17 inhibitors did not have a higher risk for the development of inflammatory bowel disease (IBD), but only after taking into account the severity of their underlying disease, French investigators reported
Read Article
FDA Approves IVIG in Dermatomyositis
The U.S. Food and Drug Administration (FDA) has approved Octagam 10% [Immune Globulin Intravenous (Human)], as the first and only intravenous immunoglobulin (IVIg) formulation to be approved for adult dermatomyositis (DM).
Read Article
Canakinumab Fails to Improve COVID-19 Survival
JAMA has published the findings of trial wherein the anti–interleukin-1β antibody canakinumab (CAN) failed to improve survival in patients hospitalized with severe COVID-19.
Read Article
ACR/Vasculitis Foundation Guideline for Giant Cell Arteritis and Takayasu Arteritis
The ACR and the Vasculitis Foundation have published their evidence-based recommendations and expert guidance for the management of GCA and Takayasu arteritis. These recommendations address a variety of clinical questions and scenarios including diagnostic testing, imaging, treatments, and surgical interventions. Recommendations for GCA and TAK include support for the use of glucocorticoid-sparing immunosuppressive agents and the use of imaging to identify large vessel involvement. Recommendations for TAK include the use of glucocorticoids as initial therapy.
Read Article
RheumNow Podcast – What Not to Do (7.16.2021)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
Read Article
ACR/Vasculitis Foundation 2021 Guidelines for ANCA–Associated Vasculitis
Chung et al have published the 2021 treatment guielines for the management of antineutrophil cytoplasmic antibody–associated vasculitis, including granulomatosis with polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis. These guidelines are put forth by the ACR and the Vasculitis Foundation as benchmark guidance to assist health care professionals in managing AAV.
Read Article
ICYMI: RheumNow Podcast – Tofacitinib Safety Concerns
Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow.com.
Read Article
ICYMI: 2020 Rheumatology Year in Review
2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related.
Read Article
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
